Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.

Afib and Hypertrophic Cardiomyopathy

Atrial Fibrillation in Hypertrophic Cardiomyopathy

Patients with hypertrophic cardiomyopathy are much more likely to develop atrial fibrillation than the general public. Patients with atrial fibrillation may develop symptoms of shortness of breath, dizziness, chest pain, and racing heart. The diagnosis is made with electrocardiogram (ECG) or ECG monitoring. Patients will frequently need to be on medications to slow the heart rate or restore normal rhythm.

In studies of patients with hypertrophic cardiomyopathy with stroke, nearly 90% of patients had atrial fibrillation. The risk of stroke appears to be less in patients with atrial fibrillation and hypertrophic cardiomyopathy having warfarin (Coumadin) anticoagulation.

Learn more about atrial fibrillation.

Condition Spotlight

Your Health: Euan Ashley, MD, Discusses Hypertrophic Cardiomyopathy Watch Video
Deadly Heart Condition Yields to Screening and Prompt Treatment
Deadly Heart Condition Yields to Screening and Prompt Treatment Read Story
Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Play Video | 59:57

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Hypertrophic Cardiomyopathy Center

See a Stanford specialist to learn about your treatment options. Visit our clinic to make an appointment.

Boswell Building
300 Pasteur Drive
Stanford, CA 94305
Phone: 650-736-7878
Visit Clinic